Parabilis Medicines Inc (PBLS)

• Market cap: $4.16B
• 1 day: 5.27%
• 5 days: 8.46%
• 1 month: 24.15%
• 3 months: 7.53%
• 6 months: 7.53%
• Year to date: 7.53%
• 1 year: 7.53%
• 5 years: 7.53%
• 10 years: 7.53%
• Sector: Healthcare
• Industry: Biotechnology

About: Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.